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Cellular quiescence is a reversible, non-cycling state controlled by epigenetic,
transcriptional and niche-associated molecular factors. Quiescence is a condition where
molecular signaling pathways maintain the poised cell-cycle state whilst enabling rapid
cell cycle re-entry. To achieve therapeutic breakthroughs in oncology it is crucial to
decipher these molecular mechanisms employed by the cancerous milieu to control,
maintain and gear stem cells towards re-activation. Cancer stem-like cells (CSCs) have
been extensively studied in most malignancies, including glioma. Here, the aberrant niche
activities skew the quiescence/activation equilibrium, leading to rapid tumor relapse
after surgery and/or chemotherapy. Unraveling quiescence mechanisms promises to
afford prevention of (often multiple) relapses, a key problem in current glioma treatment.
This review article covers the current knowledge regarding normal and aberrant cellular
quiescence control whilst also exploring how different molecular mechanisms and
properties of the neighboring cells can influence the molecular processes behind glioma
stem cell quiescence.
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FACTORS REGULATING NORMAL CELL QUIESCENCE
Stem cells are classically defined as undifferentiated cells possessing a unique ability to produce
differentiated daughter cells whilst their population maintains its stem cell state by self-renewal
(Weissman, 2000). Cancer stem-like cells (CSCs), or tumor-initiating cells, are defined as a
self-renewing subpopulation of cells within the bulk tumor mass that have the ability to recapitulate
the entire cell repertoire of the whole tumor (Chen et al., 2012).
Cell quiescence is characterized as a condition of reversible G0 phase from which cells can
escape following appropriate physiological cues. The cell quiescence is not only a dormant
state but instead an effectively maintained and directed condition, while several molecular
pathways permit the quick re-entry into the cell cycle (Cheung and Rando, 2013). The concept
of cell quiescence has changed over time. Previously, it was generally thought that cells are
forced to enter the dormant G0 phase following nutrient deprivation or contact inhibition,
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in order to avoid terminal differentiation or senescence, as this
condition was considered irreversible. Presently, it is largely
accepted that cells, particularly stem cells, enter a quiescent
state to preserve their self-renewing capacity and avoid genetic
perturbations caused by frequent division. Currently, much
attention is centered around the dynamic control of the quiescent
state of normal stem cells, which enables them to retain key
properties and genomic stability over a macro-organism lifetime.
A subset of tissue-specific stem cells is maintained in a dormant
state over prolonged time, ensuring tissue replenishment and
regeneration in normal and pathological conditions. Due to a
particular metabolic and gene expression state, quiescent stem
cells can be distinguished by their low RNA content (Fukada
et al., 2007) and the absence of proliferation markers (Gerdes
et al., 2014), as well as by label retention, explicitly demonstrating
their low turnover. However, it was recently shown that using
label retention assays alone is insufficient to properly identify
quiescent stem cells (Li and Clevers, 2010).
Thus, cell quiescence is regulated by both intrinsic and
extrinsic mechanisms. These include various transcription
factors, checkpoint regulators and protein kinases/phosphatases,
as well as extrinsic regulators, such as cell-to-cell interactions,
components of extracellular matrix (ECM) and etc. Both types
of regulators are thought to be equally important in facilitating
the dormant stem cell state and preventing their exhaustion.
Intrinsic Regulating Factors
Signaling molecules participating in the regulation of stem
cell quiescence include the tumor suppressors p53 and
retinoblastoma protein (RB), cyclin-dependent protein
kinase (CDK) inhibitors (specifically, p21, p27, p57) and
the Notch pathway (Cheung and Rando, 2013). As expected
from a non-proliferative phenotype, the quiescent stem cell
signatures are recognized as the marked downregulation of
genes involved in DNA replication and cell cycle progression.
Genes that are frequently downregulated in quiescent cells
include those encoding the important cell cycle check point
regulators, such as cyclin A2 and cyclin E2, as well as survivin
which mediates apoptosis evasion. Genes associated with
proliferation and mitochondrial function are also downregulated
in quiescent cells. Mitochondrial ATP production is a
hallmark of stem cell activation, and thus low expression of
cytochrome C (CYCS), an active participant of electron transport
chain, characterizes low metabolic activity of the quiescent
stem cell.
Conversely, genes upregulated in these cells include those
encoding signaling proteins involved in transcriptional
regulation and stem cell fate decisions such as the key
Notch pathway regulator—forkhead box O3 (FOXO3)
and H3K27 histone methyltransferases—enhancer of zeste
homologs 1 and 2 (EZH1, EZH2). For example, EZH2
knockout impairs muscle stem cell proliferation and activates
expression of non-muscle lineage genes. By contrast, EZH2
overexpression in hematopoietic stem cells (HSCs) prevents
this pool from exhaustion (Hidalgo et al., 2012). EZH1 is
a part of a noncanonical Polycomb repressive complex-2
(PRC2) mediating H3 methylation with main function of
preserving pluripotency in embryonic stem cells. Together,
these investigations propose a critical role of epigenetic
mechanisms in regulating stem cell quiescence (Shen et al.,
2008).
Adult neural stem cells (NSCs) represent a good model
for quiescence investigation as almost all NSCs in the brain
are quiescent (Fuentealba et al., 2015; Furutachi et al., 2015),
so these cells are being extensively studied for deciphering
the molecular mechanisms of dormant state. For example,
Rho-GTPase Cdc42, which is a non-canonical Wnt (ncWnt)
signaling target, was found to sustain the quiescent state
of neuronal stem cells. It was suggested that activation of
Cdc42 regulates the expression of specific factors responsible
for stem cell identity and anchorage to their niche. Glial
and neuronal lineages originate from the intermediate transit-
amplifying neural progenitors (type C cells), arising from
NSCs (type B cells) of the subventricular zone (SVZ; Lim
and Alvarez-Buylla, 2014). Moreover according to the recent
literature, vascular cell adhesion molecule-1 (VCAM-1) and
N-Cadherin are necessary to maintain quiescent NSCs (qNSCs)
within the apical niche, while absence of these proteins
disrupts quiescence and results in uncontrolled cell activation,
proliferation and differentiation, leading to rapid senescence
(Kokovay et al., 2012). NSC adhesion to the apical niche
is maintained through the ncWnt signaling, which in turn
regulates Notch signaling activity. Strikingly, as a result of a
demyelination injury, tissue homeostasis and repair depends on
the downregulation of the ncWnt/Cdc42 axis and activation of
canonicalWnt (cWnt)/β-catenin signaling in SVZNSCs (Chavali
et al., 2018).
Extrinsic Regulating Factors
Neighboring cells surrounding NSCs are also important.
Ependyma, astrocytes, active NSCs and neuroblasts present
the Notch ligands Jagged1 and Dll1 that promote NSC
self-renewal through Notch signaling (Ernst et al., 2014). The
bone morphogenetic protein (Bmp) ligands and receptors
are expressed by qNSCs, which together with Notch, Wnt,
insulin-like growth factor 2, vascular endothelial growth factor
(VEGF), and EGF signaling pathways regulate quiescence,
proliferation and differentiation in the adult neurogenic niche
(Llorens-Bobadilla et al., 2015). Normal qNSCs are thought to
enter into the cell cycle only rarely, generating actively dividing
NSCs that contribute to adult neurogenesis before returning
to quiescence. The fate of active NSCs is defined by the total
number of neighboring NSCs in a shared niche. Ependymal
cells can interfere with the differentiation of NSCs in the glial
lineage, since they are capable of producing noggin, an inhibitor
of BMP cascade. Additionally, they express CXCR4, the receptor
for the stromal cell-derived factor-1 (SDF-1) or CXCL12,
which expression is induced by proinflammatory cytokines and
association with the Sonic Hedgehog (Shh) signaling cascade
during brain development. As the NSC niches are frequently
arranged in a perivascular zone, the vessel framework effectively
controls the neurogenic procedure. In addition, neurogenesis
and vessel formation is controlled by similar elements including
IGF-1, bFGF, VEGF and TGF-α (Fidoamore et al., 2016).
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There is still more questions then answers as to which
molecular mechanisms regulate the transition from quiescent
to active proliferative state. Wnt target Tnfrsf19/Troy was
very recently found to be a mark of both active and
qNSCs (Basak et al., 2018). Transition to proliferation
may also be mediated by the high mobility group (HMG)
proteins—nonhistone chromatin proteins that affect gene
expression by increasing the accessibility of DNA in
chromatin for its binding by transcription factors (Thomas
and Travers, 2001). Indeed, they have been reported to
mediate NSC differentiation. For instance, the HMG
AThook 2 (HMGA2) protein is highly expressed in the
ventricular zone of the embryonic brain, where NSCs are
thought to reside (Sanosaka et al., 2008). Moreover, during
embryonic stages, HMGA1 and HMGA2 promote neuronal
differentiation while inhibiting astrocyte differentiation of
NSCs (Ozturk et al., 2014). HMGB1 and HMGB2 were listed
as especially over-expressed during the activation of qNSCs
in the adult dentate gyrus (Shin et al., 2015). Addittionally,
HMGB2 expression is strongly associated with transition from
the quiescent to the proliferative state of NSCs (Kimura et al.,
2018).
The Notch pathway was shown to be a key regulator of the
quiescence-proliferation balance in stem cells. NOTCH1 is
predominantly expressed in active NSCs and transit-
amplifying progenitors, while NOTCH3 is preferentially
expressed in qNSCs. NOTCH3 knockdown in the lateral
wall of adult subependymal zone (SEZ) increases NSC
division. Furthermore, NOTCH3 deletion reduces the number
of activated qNSCs as a result of antimitotic treatment.
Importantly, NOTCH3 deletion preferentially reduces
specific subtypes of newborn neurons in the olfactory bulb
derived from the lateral walls of the SEZ (Kawai et al.,
2017). However, the most recent report pointed Notch2,
but not Notch1, being indispensable for maintaining the
population of qNSCs in the mouse SVZ, as it represses the
cell-cycle and the neuronal differentiation genes (Engler et al.,
2018).
Thus, the quiescent state is a practical way for normal stem
cells to preserve their pool in tissues while retaining genetic
stability and proliferative potential. NSCs can exist in two states:
the actively dividing progenitor and the quiescent cell. The
transition between these two states is peformed by activating
certain molecular pathways, such as Wnt, Notch, Shh, while the
certain mechanisms still elude the scientific community. The
neighboring cells also provides a control for stem cell regulation
by keeping them unresponsive to certain non-threshhold factors,
but ensuring fast activation of stem cells in case of injury or other
massive cell loss.
GLIOMA STEM CELL MOLECULAR
PROFILE
Glioma cells are now believed to originate from a neural
stem cell of different commitment state (Alcantara Llaguno
and Parada, 2016), therefore ‘‘glioma stem cells’’ and NSCs
share common phenotypic markers (CD133, CD44, CD15),
as well as activated molecular pathways. Nevertheless,
glioma stem cells can be distinguished as they carry
particular genetic alterations favoring their continuous
division without senescence. Here we describe molecular
signatures of different glioma types as they have been
thoroughly investigated during the last decade thanks to
high throughput techniques, such as whole genome and whole
exome sequencing.
Astrocytoma Molecular Signatures
According to WHO classification released in 2016, all gliomas
can be classified by key genetic alterations into three types:
astrocytoma, oligodendroglioma and glioblastoma (primary
and secondary; Louis et al., 2016). The molecular signature
of astrocytomas includes IDH mutation, TP53 mutation and
functional loss of ATRX (Figarella-Branger et al., 2012). The
most frequent IDH mutation is the substitution of arginine
for histidine at codon 132 (R132H) representing 92.7% of all
mutations occurring in the IDH1 gene. In the IDH2 gene,
R172K substitution represents 65% of all IDH2 mutations
followed by R172M (19%), and R172W (16%; Hartmann
et al., 2009). Approximately two-thirds of the IDH-mutant
gliomas have an intact 1p/19q, and of these 94% have TP53
loss of function or other mutation and 86% have ATRX
inactivation, which is involved in chromatin remodeling and
DNA methylation (Brat et al., 2015). Nearly all ATRX-
mutated gliomas also harbor TP53 mutations and it was
discovered that TP53 mutations occur first and predispose
towards the acquisition of ATRX loss of function (Cryan et al.,
2014).
Oligodendroglioma Molecular Signatures
Oligodendrogliomas are characterized by the presence of
mutations in IDH1/2 alongside 1p/19q codeletion but almost
never acquire alterations in TP53 or ATRX (signature of
astrocytomas), as well as copy number amplification (signature
of glioblastoma; Reuss et al., 2015). A large proportion of
IDH1/2-mutant and 1p/19q codeleted tumors also contain
inactivation mutations of tumor suppressor genes—CIC and
FUBP1 with a frequency of 20%–30% and 46%–83%, respectively
(Bettegowda et al., 2011; Wesseling et al., 2015). Additionally,
96% of tumors with IDH1/2 mutations and 1p/19q codeletion
harbor mutation in the TERT promoter (TERT-p; C228T
or C250T), which is extremely rare (only 4%) in IDH1/2-
mutant 1p/19q intact tumors. However, IDH-wt tumors also
commonly acquire TERT-p mutations, conferring cells with
the ability to extend telomeres and bypass the Hayflick limit
(Eckel-Passow et al., 2015). Interestingly, TERT-p mutation
in combination with IDH1/2 alterations brings favorable
prognosis, while in IDH-wt tumors it is associated with worse
outcome, indicating the existence of an interaction between
mutations.
The presence of similar mutation signatures in the IDH
gene for astrocytomas and oligodendrogliomas highlights the
possibility of a common progenitor cell for these two types
of tumor, whereas IDH-wt glioblastomas (GBMs) are believed
to arise from a different cell of origin. It is hypothesized that
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acquisition of certain mutations drives a malignant cell to
‘‘differentiation’’; either to astrocytoma by obtaining TP53 and
ATRX mutations or to oligodendroglioma by losing 1p and
19q (Ohgaki and Kleihues, 2013). However, induction of
IDH R132H mutation in neural stem cells leads to either
predominant differentiation to neurons (Lu et al., 2012) or
to differentiation block and increased apoptosis (Rosiak et al.,
2016). Similarly, introduction of IDH1 R132H in combination
with TP53 and ATRX knockdown leads to differentiation
block in NSCs via transcriptional silencing of SOX2 (Modrek
et al., 2017). Thus the incorporation of IDH1 mutation
solely results in decreased proliferation ability because of
p53-mediated cell cycle arrest, which can be bypassed by
TP53 loss (Pirozzi et al., 2017; Zhang Y. et al., 2018),
while ATRX mutation confers the cells with infinite growth
ability by alternative lengthening of telomeres (Amorim et al.,
2016).
CIC is a downstream component of receptor kinase
(RTK) pathways (RTK–RAS–RAF–MAPK) and blocks
transcription through binding to a regulatory region. It is
negatively regulated by RTK signaling which blocks the
function of CIC through MAPK-mediated phosphorylation
and subsequent degradation. FUBP1 mutations may result
in MYC activation or ribosome biogenesis. The additional
impact of these alterations on the outcome of patients with




In contrast to oligodendroglioma and astrocytoma, primary
IDH1/2-wt GBMs are more genetically heterogeneous and do
not have mutations defining the majority of the cells within
the tumor, thus they are referred to as IDH-wt. Absence of
marker alteration makes it difficult to suggest the cell of origin
and to define initiating or driver mutations for primary IDH-wt
GBMs. The majority of primary GBMs are IDH-wt gliomas
(95%), while low grade gliomas are IDH-wt in only 20%–25%
cases (Parsons et al., 2008). The most frequently altered genes
in IDH-wt GBMs include CDKN2A (50%); TP53, epidermal
growth factor receptor (EGFR) and PTEN (30%–40%); as well as
CDK4, NF1 and Rb1 (12%–15%; Ceccarelli et al., 2016). Almost
half of GBMs harbor mutation, rearrangement, or amplification
of EGFR (Brennan et al., 2013). Approximately 50% of
EGFR-amplified tumors acquire the variant III (EGFRvIII)
deletion of exons 2–7 that results in constitutive activation
of downstream receptor tyrosine kinase signaling (Verhaak
et al., 2010; Appin and Brat, 2015). Approximately 15%–18%
of primary IDH-wt GBMs carry PDGFRA amplifications while
MDM2 and CDK4 amplifications are present in 5%–15% and
14%–18% of the cases, respectively (Aldape et al., 2015). BRAF
V600E mutations are rare in GBMs (Aldape et al., 2015;
Takahashi et al., 2015), but can be associated with better
prognosis for patients (Vuong et al., 2018). Interestingly, BRAF
V600E never occurs alongside IDH1/2 mutations and may also
define a subgroup of slowly progressing gliomas with better
treatment response (Chi et al., 2013). It is clear that like in tumors
with IDH1/2 mutations, BRAF V600E can alter cell methylation
profiles, however the reports about extent and mechanism of
this methylation changes are controversial (Hinoue et al., 2009;
Hou et al., 2012; Bond et al., 2018), emphasizing the necessity
for further investigation. Large alterations affecting entire
chromosomes are also typical for primary GBMs, specifically
chromosome 7 gain and chromosome 9p and 10 loss which
present in more than half of primary GBMs. Chromosome
7 contains EGFR, the second most altered gene in IDH-wt
GBMs. Chromosome 9 contains tumor suppressor genes such as
CDKN2B/p15 and CDKN2A/p16 controlling Rb and p53, and
chromosome 10 encompasses PTEN, DMBT1 and LGI1 genes
regulating cell growth and cycle progression (Crespo et al.,
2011). In primary GBMs, IDH mutations are found at a very
low frequency (less than 5%). IDH-mutant gliomas diagnosed
as primary GBMs are likely progressed astrocytomas that
evaded earlier diagnosis (Ohgaki and Kleihues, 2013), as they
frequently contain astrocytoma signature mutations—IDH1
(85%), TP53 (81%) and ATRX (71%; Liu et al., 2012). The
transition of anaplastic astrocytomas to secondary GBMs
is likely to be driven by acquiring chromosome 10q loss,
which is characteristic of primary GBMs, but is found in
more than 60% of secondary GBMs (Ohgaki and Kleihues,
2013).
Thus, it is likely that oligodendroglioma and astrocytoma
arise from a common precursor cell, such as NSC, because they
harbor the same mutation in IDH1/2, which is probably the
initiating event in gliomagenesis. Primary IDH-wt GBMs possess
markedly different key genetic alterations and in general are
more heterogeneous. Therefore, it is likely that IDH-wt GBMs
arise from a different precursor cell than IDH-mutant gliomas.
Glioma Stem Cells Molecular Signatures
It is important to note that, to date, it has not been
possible to discriminate between the more quiescent, long-term
self-renewing NSCs and the more rapidly dividing progenitor
cells. In general, CSCs derived from GBM tumors are
characterized by similar mutational arrangement. Specifically,
typical GBM CSC populations harbor homozygous CDKN2A
deletion, EGFR gain (up to four copies), and alterations
in KCN5, PLCB2, GDF5 and/or TRMT5. Loss of wild-type
TP53 gene occurrs following EGFR amplification of more than
four copies, while heterozygous TP53 and PALB2 mutations
occurr upon EGFR amplification beyond this (Piccirillo et al.,
2015). Interestingly, certain point TP53 mutations (c.565G >A
and c.451C >T) were shown to mediate therapeutic resistance,
as they associat with the relapsing GBM CSC phenotype (Orzan
et al., 2017). Additionally, several novel mutations were reported
to be hallmarks of GBM CSCs, including alterations in CENPF
playing a role in chromosome segregation during mitosis,
AJAP1 being tumor suppressor gene, and hypermethylation of
the tumor-suppressor gene EMP3 (Ernst et al., 2009). Several
researchers characterized glioma CSCs as a cell population
with impaired gene expression rather than certain genomic
alterations, for instance, hyperactivity of the cell cycle genes
(IGFBP5, VEGFA, SLC2A3, LGALS3, FAM115C, MT1X, UBC,
C4orf3, FAM162A, PPP1R15A, EEF1A1, FTL; Patel et al., 2014),
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increased expression of neurodevelopmental TFs (POU3F2,
SOX2, SOX4, SOX11, SALL2 and OLIG2; Tirosh et al., 2016), or
NSC-related genes (NFIB, ASCL1, CHD7, CD24, BOC and TCF4;
Suvà et al., 2013) were proposed to confer stem-like properties to
malignant cells enabling them to convert to CSCs. Additionally,
primary GBM cell lines grown as neurospheres were shown to
upregulate genes involved in immune modulation—TNFSF18,
CXCL16, CX3CL1, regulation of apotosis—PRKG1, growth and
survival—PDGFRA, met, DLL1 compared to the same cells
grown as adherent culture (Wilson et al., 2016). While CSCs
are being extensively studied in GBM, the presence of this
population in low grade gliomas is still arguable, with only a
few studies reported to describe genomic and transcriptomic
features of CSCs from grade II and III astrocytomas or
oligodendrogliomas where they were defined as cells expressing
corresponding lineage specific genes along with the elevated
expression of cell cycle genes or neural TFs (Tirosh et al.,
2016; Venteicher et al., 2017). Meanwhile, evidence suggests that
CSCs arise from a common progenitor with signature genetic
mutations in CDKN2A/B, EGFR and TP53 (Sottoriva et al.,
2013).
The molecular signatures of gliomas allow clinicians to make
reliable diagnosis and prognosis for patients. How these genetic
events drive malignant transformation are being extensively
studied but key questions remain. Why do several mutations
lead to favorable prognosis and gliomas with less malignant
phenotype?What is themutual effect ofmutations on each other?
FACTORS REGULATING GLIOMA STEM
CELL QUIESCENCE
Little research has been reported to address potential roles
quiescence might play in CSC biology. In cancer biology, tumor
dormancy designates a frequent clinical phenomenon in which
disseminated tumor cells are maintained in a nonproliferating,
quiescent state for long time intervals. This phenomenon may
occur at early stages of the disease or following therapeutic
intervention. Awakening of these dormant cells leads to tumor
progression and relapse which may occur after very long periods
(Sosa et al., 2014).
The considerable lack of studies specifically investigating
the quiescent CSCs is most likely because of difficulties in
isolating CSC populations and demonstrating their stem cell
properties. Considering that CSCs originate from adult stem
cells, the molecular signatures of quiescent CSCs should include
such markers as Hes1 (Notch signaling), p21, p16INK4a, Rb,
Bmi-1. In fact, quiescent CSCs have similar gene expression
signatures to normal dormant stem cells, for example, they
downregulate the expression of genes associated with cell cycle,
such as, cyclin B1, Cdc20, Cul-1, ubiquitinating cell cycle
proteins, and Myc, while upregulate the expression of classical
cell cycle controllers, such as, TP53 and MAX-interacting
protein 1. Interestingly, quiescent CSC signatures include
upregulation of cyclin D2 which is required for G1/S transition
in the cell cycle and should normally lead to the evasion of
G0 phase. A possible explanation can be that several genes
highly expressed in quiescent CSCs ensure their poised state
to quickly re-enter the cell cycle if needed. Other signatures
of quiescent CSCs include fundamental modulators of key
molecular pathways including the Wnt (FZD2 and TCF7L2),
BMP (SMAD1) and Notch pathways (Hes1). Interestingly,
CSCs acquiring mutations in Rb or its related protein
p107 are unable to maintain a quiescent state while still
preserving the ability to enter G0 phase (Moore and Lyle,
2011). Here we describe the major pathways that were
reported to play a role in cellular quiescence: Wnt cascade,
Notch, TP53, Akt/mTOR and hypoxia-inducible factor 1 alpha
(HIF1α).
Canonical/Non-canonical Wnt Cascade
ncWnt signaling has been shown to be a crucial regulator of
qNSCs within their niche, through the activation of Rho-GTPase
Cdc42 which controls the apical adhesion of qNSCs. Moreover,
it was found that transient activation of canonical the Wnt
cascade is important for activation and propagation of qNSCs,
highlighting the importance of a canonical-non-canonical switch
in regulation of temporal quiescence in normal NSCs (Chavali
et al., 2018). Additionally, ncWnt maintains quiescent HSCs
through key components mediating cell polarization—Flamingo
(Fmi) and Frizzled (Fzd) 8 (Sugimura et al., 2012). CD44,
CD133 and LGR5 are characteristic cell surface markers of
glioma CSCs (Lathia et al., 2015), which are either receptors
for cWnt pathway (LGR5), or function as positive regulators
of Wnt receptors (CD44; Schmitt et al., 2015), or E-cadherin
(CD133; Brossa et al., 2018). In CSCs, cWnt signaling is
mostly activated by ligands such as WNT2B and WNT3 which
are secreted by tumor niche cells. These genes also can be
upregulated as a result of genetic alterations in the cWnt/β-
catenin cascade molecules, such as gain-of-function (GOF)
mutations in the CTNNB1 (β-catenin) gene and loss-of-function
mutations in the signaling regulators, such as APC, AXIN1,
AXIN2, RNF43 and ZNRF3 genes (Katoh, 2017). However,
cWnt signaling is involved mostly in CSC expansion and tumor
growth, but not in preservation of CSC stemness through
maintaining a quiescent state. Additionally, it was shown that
major cWnt signaling molecules, such as β-catenin and GSK3β
are not expressed in glioma cells highlighting the possibility of
other pathways driving glioma progression (Zhang H. et al.,
2018).
ncWnt signaling through RTKs can activate the PI3K-Akt
signaling cascade and affect cell cycle progression. As ncWnt
signaling maintains quiescence of stem cells and inhibits
cWnt signaling, it has been considered primarily a tumor
suppressor. However, experimental data on the ncWnt cascade
in glioma is limited and focused mainly on cell invasiveness
and migration. To this end, Cdc42 was shown to drive cell
mobility in glioma (Okura et al., 2016), while expression
of Wnt5a (initiating ligand of ncWnt) in glioma CSCs
leads to their differentiation into endothelial-like cells (Hu
et al., 2016). Inhibition of Wnt signaling in glioma CSCs
leads to loss of stem cell properties (Bhuvanalakshmi et al.,
2015) while the expression of Fzd4 in glioma cells is
associated with increased stemness and invasiveness (Jin et al.,
2011).
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It is apparent that the ncWnt cascade plays a significant role
in glioma CSC quiescence. It is of interest to explore the role
of Rho-GTPases in regulating cell polarity and Fzd receptors for
their potential to induce dormancy and highly therapy-resistant
glioma cells.
TP53/Rb
Limited data exists on the extent of which p53 plays a
role in quiescence, but there is a lot of evidence of mutant
p53 contribution to cancer progression in general and very
few studies highlighting its role in CSC maintenance (Chavali
et al., 2018), and even less in maintaining quiescence. For
example, it was demonstrated that an additional copy of wild
type p53 increased quiescence and ciliated cell differentiation
(McConnell et al., 2016), by means of recruiting histone
deacetylase 1 (HDAC1) to the CD133 promoter which causes
reduced histone H3 acetylation and subsequently leads to
restricted growth and proliferation (Park et al., 2015). However,
mutant p53, especially hotspot GOF mutations were shown
to have a driver role in oncogenesis (Olivos and Mayo,
2016). Three most common hotspot mutations found in
p53, namely R175, R248Q and R273H, were mapped to the
DNA binding domain where they cause single amino acid
substitutions (Lawrence et al., 2014). GOF mutant R175H
and R273H p53 proteins trigger cell transformation through
the involvement of mTOR signaling (Dando et al., 2016).
In this case, the mutant p53 mediates signaling through
growth factor receptors (GFRs), such as EGFR and hepatocyte
growth factor (HGF) receptor, thus promoting PI3K/Akt
signaling and downstream activation of mTORC1 (Yallowitz
et al., 2015). p53 R175H has been shown to upregulate
TWIST1 expression and subsequently decrease the histone
H3 methylation upstream of the TWIST1 promoter (Kogan-
Sakin et al., 2011). TWIST1 ectopic expression in neural
crest cells was implicated in cell lineage determination and
differentiation, as it represses pro-neural factors to prevent loss
of stem cell properties (Vincentz et al., 2013). Additionally,
all three p53 GOF mutations can alter chromatin binding
states by upregulating chromatin regulatory genes, including
the methyltransferases KMT2A (MLL1) and KMT2D (MLL2),
and acetyltransferase KAT6A (MOZ or MYST3), resulting in
genome-wide increases of histone methylation and acetylation
(Zhu et al., 2015). All these chromatin modulators have been
shown to participate in quiescence maintained in healthy stem
cells. For example, MLL1 deficiency was shown to abrogate
a pool of adult quiescent HSCs (Jones et al., 2015), KMT2D
was reported to be essential for maintaining a pool of cardiac
precursors (Ang et al., 2016), as well as for preserving the
population of adult HSCs and progenitors, because HSCs
lacking Mll exhibit increased cell cycling which results in
the depletion of quiescent HSCs (Jude et al., 2007). In the
same manner, loss of acetyltransferase KAT6A in adult mice
leads to the rapid loss of adult HSCs with a concurrent
reduction in the population of quiescent cells in G0 phase
(Sheikh et al., 2016). Thus, p53 GOF mutations can be of
major importance in maintaining quiescent CSCs as they
are implicated in gene expression via recruiting transcription
factor, binding to promoter sites of protooncogenes, or
through regulation of chromatin modifying enzymes, but the
molecular mechanism of this regulation in CSCs is still to be
discovered.
HIF1/Notch/p38
Another important contributor to inducing quiescence is
hypoxia and its key molecular regulator, HIF1α. HIF1 positive
quiescent glioma stem cells were localized in perinecrotic
niches within glioblastoma tissue. HIF1α importance in glioma
is highlighted by the fact that mutations in IDH1/2 can
lead to accumulation of HIF1α (Zhao et al., 2009; Xu et al.,
2011), however the most recent report states otherwise
(Koivunen et al., 2012). Establishing tumor cell lines from
IDH-mt low grade gliomas is challenging as the IDH
mutant clones tend to be eliminated during conventional
culturing, leading to the conclusion that IDH mutant cells
do not possess self-renewing properties (Kelly et al., 2010;
Stoczynska-Fidelus et al., 2014). However, it is possible that
IDH-mt cells contain HIF1α-induced quiescent stem cells
which in normoxic conditions lose their stem potential
because of HIF1α inhibition. Additionally, HIF1α and
HIF2α were shown to be responsible for acquiring stem
cell properties in differentiated glioma cells. Long-term
exposure of glioma cell lines containing small stem cell
populations to therapeutic stress (temozolomide) conferred
differentiated glioma cells with stemness and pluripotency
markers, such as CD133, SOX2, Oct4 and Nestin, whilst
also upregulating HIF1/2α expression (Auffinger et al., 2014;
Lee et al., 2016). However, these two reports demonstrated
that HIF1α was coexpressed with proliferation marker ki67,
which is against widely accepted idea that HIF overexpression
leads to cell cycle arrest through derepression of p21 and
p27 (Gardner et al., 2001; Goda et al., 2003). In contrast,
HIF2α was shown to have opposite properties and promote
cancer cell proliferation through augmentation of c-Myc
activity (Gordan et al., 2007). This highlights the problem
of lack of comprehensive study in this field, as well as
the necessity of taking into account signature mutational
profile of the glioma cells to provide more complete
information.
HIF1α was also investigated in conjunction with Notch
signaling, where it was shown to contribute to glioma CSC
maintenance through stabilization of the intracellular domain of
Notch (NICD; Qiang et al., 2012). In the brain, Notch signaling
controls the state of normal stem cells by facilitating the quiescent
state of radial glial cells and preventing neuronal differentiation
of progenitors and NSCs (Ables et al., 2011). However, in
cancer Notch acts an oncogenic signaling factor, facilitating
glioma CSCs transition to quiescent state. Liau et al showed
that glioma CSCs can temporarily transition to a dormant state
in response to RTK inhibitors. Culturing with high level of
RTK inhibitors also led to upregulated expression of various
Notch pathway genes which were shown to be essential for
cell survival under RTK inhibitory conditions. This condition
was shown to be reversible even after prolonged cell cultivation
in the slow-cycling state with the capability of restoring high
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proliferation rate and subsequent downregulation of Notch genes
(Liau et al., 2017). However, not all reports refer to Notch
signaling as oncogenic driver, Giachino et al. (2015) reported
that suppression of key Notch mediators and receptors, such
as RBP-Jk, (a transcriptional repressor in the absence Notch
molecules), as well as Notch1 and Notch2 induced glioma
growth in mice. They proposed a model in which Notch and
wild type TP53 act in cooperation and promote tumor growth
restriction and cell cycle arrest in glioma cells (Giachino et al.,
2015). However, it is possible that these pathways can interplay
to promote not only growth restriction but a quiescent state,
especially if the Notch cascade coordinates with TP53 GOF
mutations.
p38 is a subgroup of mitogen-activated kinases that plays
a significant role in cell cycle, differentiation and apoptosis.
Inhibition of p38 leads to a decrease in both in vitro and in vivo
glioma stem cell proliferation. The p38 pathway was suggested to
affect survival, cell cycle state and differentiation status of glioma
CSCs via regulating EGFR trafficking. These observations led to
the conclusion that while p38 inhibition of glioma CSCs resulted
in diminished proliferative activity, differentiated cancer cells
composing the tumor body maintained the slow-cycling glioma
CSC state by blocking differentiation into terminal lineages
(Soeda et al., 2017).
PTEN/Akt/mTOR
Numerous investigations have demonstrated that the role of
the tumor silencer protein PTEN in cell cycle progression
is essential for tumor elements. In low grade gliomas PTEN
keeps cells in G1 while the loss of its action is habitually
seen in high grade gliomas. PTEN regulates cell cycle related
proteins through control of Akt phosphorylation which leads
to FoxO1 translocation to the cytoplasm and subsequent
repression of Notch pathway (Yue et al., 2017). Additionally,
Akt regulates important cell cycle regulators such as E2F2,
cdc25a, Cyclin G2 and RBL2 (Choi et al., 2017). The
significance of Akt signaling in maintaining quiescent glioma
CSCs was also emphasized in previous investigations. The
Akt-mTORC2 axis was revealed as a signaling pathway
ensuring CSC ability to quit G0 phase. In this case, altered
metabolic state of activated cells leads to Akt phosphorylation
at T308 by phosphoinositide-dependent kinase-1 (PDK1).
Activated Akt in turn phosphorylates mTORC2 component
Sin1 leading to a second phosphorylation of Akt at S473 and
its full activation (Yang et al., 2015). Moreover, the IKK
complex, controlling NF-κB activation and proinflammatory
response, can also control mTORC1 and mTORC2 via
Akt-dependent regulation (Dan et al., 2016). Additionally,
AKT1-low cells were reported to enter a temporarily quiescent
state meaning that low Akt levels ensure the ability to induce
a dormant state. Quiescent CSCs can likewise upregulate
the JARID1B histone demethylase and thereby become more
quickly cycling cells with AKT1-high/JARID1B-high profile
(Facompre et al., 2016). This represents a relative simplicity
of G0 phase exit for CSCs and highlights the importance
of epigenetic regulators in this transition, which still lacks
proper investigation. Surprisingly, a mutant AKT1 form (E17K
substitution) which is considered an oncoprotein, can specifically
downregulate the ability of proliferative cancer cells to enter
the G0 dormancy state, thus precluding the formation of
quiescent CSC pool (Alves et al., 2018). This discovery leads
us to the point that some cancer-associated mutations could be
advantageous and should be investigated from a different point
of view.
The dormant statemight be effectively prompted by particular
kinases including double specificity tyrosine phosphorylation-
managed kinase 1A and B (DYRK1A and DYRK1B). DYRK1A
was shown to be crucial for quiescence maintenance by
inducing Cyclin D3 degradation, which ensures E2F mediated
gene transcription (Thompson et al., 2015). Similarly, the
DYRK1B kinase induces Cyclin D degradation by stabilizing the
cdk inhibitor p27 and DREAM complex, regulating cell-cycle
dependent gene expression (Becker, 2017).
Thus, quiescence of glioma stem cells can be regulated by
pRb, p53, ncWnt, PTEN and FoxO to enter the quiescent state,
and by Akt, mTORC1, cWnt, Notch, CDK3/cyclin C to exit
G0 (summarized in Figure 1). The quiescent state of CSCs
enables these cells to acquire resistance to commonly used
antiproliferative agents. A treatment strategy forcing quiescent
CSCs to enter cell cycle was termed the ‘‘locked out’’ strategy,
which could bring a therapeutic benefit with acceptable risks to
FIGURE 1 | Molecular mechanisms underlying entrance and quite G0-phase
of cell cycle by cancer stem-like cells (CSCs). Conventional four phases of the
cell cycle are regulated by a specific complex of cyclin and cyclin-dependent
kinase (CDK). The regulatory machinery of G1 progression overlaps with
decision mechanism about the commitment to quiescence or proliferation. In
case of GFs/mitogens availability, CDK4/6/cyclin D complex phosphorylates
Rb causing E2F release, which in turn activates cyclin E. CDK2/cyclin E
complex drives G1 to S phase transition. CDK4/6/cyclin D complex also
removes p21 and p27 inhibition on CDK2. Cells in G1 phase can exit the cell
cycle and enter G0 phase as quiescent, senescent, or differentiated cells. In
case of nutrition withdraw or hypoxia, Rb renders E2F bound and as a result
CDK2/cyclin E complex is inhibited by p21/p27. Alternatively, activation of
non-canonical Wnt (ncWnt) signaling causes quiescence induction via
Rho-GTPase/Cdc42 complex. PTEN causes G0 entrance by inhibiting
CDK4/6/cyclin D complex or Akt pathway. As a result, cells are driven into
quiescence. CDK3/cyclin C complex, Notch, canonical Wnt (cWnt) signaling,
or Akt/mTORC1 pathway can drive cells to enter cell cycle again. In response
to mTORC1 signaling, quiescent cells can transit into the GAlert phase and
become poised for rapid cell cycle entry.
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patients with high grade cancers (Takeishi et al., 2013). However,
the ‘‘locked out’’ approach may be of too high risk as massive
induction of cancer cell proliferation can result in enhanced
genetic heterogeneity and selection of highly resistant cell clones
(Sosa et al., 2014).
SYMMETRIC AND ASYMMETRIC STEM
CELL DIVISION AND MAINTENANCE OF
GLIOMA PLASTICITY
Previously it was generally accepted that new neurons
can be generated only in the neurogenic phase during
embryonic development. However, current studies have
clearly demonstrated that neurogenesis is sustained in
postnatal stages along with the production of glial cells. The
differentiation hierarchy begins from stem cells generating
transit amplifying cells, which in turn develop lineage-
committed progenitor cells finally resulting in mature cells
of various types. The brain analog of embryonic stem cells is
derived from the neural tube from which neuroepithelial cells
arise. Neuroepithelial cells serve as progenitors for radial glial
cells, which then mostly reside in the SVZ surrounding the
lateral ventricles and in the subgranular zone (SGZ) of the
dentate gyrus within the hippocampus, where these cells persist
throughout adulthood. In this context radial glial cells can
be termed as NSCs, as they function as a primary progenitor
for neurons and astrocytes (Kriegstein and Alvarez-Buylla,
2009).
Models of Stem Cell Division
There are three primary models describing the nature of
neuro- and glio-genesis in the adult human brain: classical
(division asymmetry), stochastic (population asymmetry) and
disposable stem cell models. The first paradigm proposes
that NSCs undergo asymmetric cell division resulting in the
emergence two different cells, where only one daughter cell
preserves the stem self-renewing properties while the other
differentiates into a transient amplifying cell through a series
of terminal, symmetric divisions (Bond et al., 2015). In this
model, following entry of qNSCs into the cycle, only one
daughter cell returns to quiescence, while the other differentiates
directly or through a series of terminal divisions. Alternatively,
the fate behavior of NSCs could be stochastic in the sense
that, upon activation, one active NSC returns to quiescence
for every quiescent NSC entering the cell cycle. In the first
model, only qNSCs maintain long-term self-renewal potential
while, in the second, self-renewal potential is shared by quiescent
and active NSCs and achieved only at the population level
(population asymmetry model). The third possibility is that
the quiescent NSC pool is disposable, in the sense that,
once activated, they either differentiate or remain in the
cell cycle and become exhausted over time (Basak et al.,
2018).
Now there is a new emerging niche restricted model,
which suggests that a constant rate of qNSCs become
activated sporadically and enter into cycle, while another
population of activated NSCs stochastically return to quiescence.
During their active phase, NSCs may independently and
stochastically choose between cell duplication, giving rise to
two active NSCs, and a symmetric differentiating division
generating two transit amplifying cells. The division of active
NSCs results in cell duplication or differentiation with a
probability that depends on the total number of existing
NSCs (active or quiescent) in the local niche (Basak et al.,
2018).
Recently, growing evidence supporting the disposable model
has been provided by genetic lineage tracing and live imaging
studies, which suggest that activated NSCs inevitably lose
neurogenic potential (Calzolari et al., 2015). Studies utilizing
direct visualization of radial glia as well as invertebrate models
placed their emphasis on invariant asymmetric cell division
(Paridaen and Huttner, 2014). However, despite the fact that
evidence supporting either niche-directed asymmetric NSC
division or the spontaneous segregation of fate determinants is
currently lacking, the asymmetry model is still considered the
most widespread in NSC differentiation.
Pathways Regulating Asymmetric Stem
Cell Division
Asymmetric cell division implies the unequal distribution of cell
fate determinants between daughter cells which is achieved by
the establishment of cellular polarity prior to mitosis (Lewis
and Petritsch, 2013). The maintenance of neuroepithelial and
radial glial cell polarity is accomplished by tight junctions at the
apical and basal cell sides by the adaptor proteins Numb and
Numbl, which promote cell cycle withdrawal by downregulating
signaling of GFR ERBB2 (Hirai et al., 2017).
According to the division asymmetry model, neuroepithelial
cells can simultaneously produce several more differentiated
descendants, specifically, radial glial cells, basal progenitors and
neurons. Cell fate decisions depend vastly on the predominant
TFs and activated molecular pathways inherited by either
daughter cell. The formation of radial glial cells occurs when
the expression of Sox1 is substituted by the expression of
paired type homeobox 6 (Pax6), a pivotal TF for brain
patterning (Curto et al., 2014). The production of transient
amplifying cells from asymmetrically dividing radial glial cells
is determined by reduction of Pax6 expression in favor of
Tbr2, a transcription factor expressed in postmitotic basal
cells and projection neurons, which is in turn replaced by
Tbr1, when cells acquire a terminal neural phenotype (Englund
et al., 2005; Ghosh et al., 2017). Proposed hierarchy of
NSCs is depicted in Figure 2A. More recently, radial glial
cells that leave the ventricle zone to migrate to SVZ and
retain basal fiber and Pax6 expression, have been termed
as outer glial cells. These cells are capable of asymmetric
division with simultaneous production of a basal progenitor and
neuron (Wang et al., 2011). The ultimate fate of outer glial
cells is regulated by integrin signaling and its differentiation
leads to loss of both apical and basal polarity (Fietz et al.,
2010).
Both neuroepithelial and radial glial cells are polarized
epithelial cells, with different surface regulators expressed on
each side, the so-called apical, basal and lateral membranes, each
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FIGURE 2 | Stem cell hierarchy and division. (A) Normal neural stem cells (NSCs) hierarchy: neuroepithelial cells expressing signature transcription factor—Sox1, are
polar cells capable of asymmetric division. Apical parts of the cells are enriched with Par3, Par6 and musashi-1 (Msi); basal parts collect cyclin D. Neuroepithelial cell
through division can generate more differentiated cells—radial glial cells expressing paired type homeobox 6 (Pax6), which are also polar and can divide
asymmetrically. They can produce more differentiated cells—transit-amplifying cells, expressing Trb2 and capable of fast expansion. They can divide only
symmetrically and committed to differentiation in neuroblasts. Neuroblasts are symmetrically dividing nonpolar cells expressing Trb1. (B) CSCs hierarchy in glioma.
Initiating glioma CSCs expressing embryonic transcription factors—Oct4, Sox2 and Nestin. These cells are probably capable of asymmetric division with generation
of more differentiated cells expressing stem cell markers—CD133, CD44 and CD15. Separation of glioma CSCs on less differentiated and more differentiated is not
strict as the phenotype of these cells highly depends on the phenotype of the cell of origin. CSCs can generate more differentiated cells with progenitor markers:
PSA-NCAM and Doublecortin which amplify the general tumor cell pool and can become more differentiated with generation of cells expressing β-tubulin-III, glial
fibrillary acidic protein (GFAP), OLIG2, SERPINE1, TGFB1, RELB. (C) Stem cell symmetric and asymmetric division. NSC can divide asymmetrically by generating
two daughter cells with different fate: one cell inherits EGFR and Cyclin D that poise the cell to rapid symmetric cycling, and the other gets Numb, Par6, Par3 and Msi
preventing differentiation programs. If during symmetric or asymmetric division NSC experiences the influence of ncWnt, TP53, or hypoxia-inducible factor 1 alpha
(HIF1α) pathways it can enter the quiescent state. If quiescent NSC receives signals from cWnt, mTORC1, or Notch pathways it can enter cell cycle and divide
symmetrically or asymmetrically.
of which can be exclusively characterized by specific molecular
markers, such as prominin-1 and cadherins, respectively. When
the asymmetric division occurs the more basal daughter cell
inherits a positive regulator of G2 progression—cyclin D2, which
is concentrated in the basal process of the polar cell, thus
predetermining cellular fate (Tsunekawa et al., 2012). Differential
cell fate determination is a result of distinct distribution of
signaling effectors, including EGFR (Sun et al., 2005), polarity
regulators Par3 and Par6 (Gómez-López et al., 2014), and
neural RNA-binding protein Musashi-1 (Msi1), all of which
were shown to preferentially colocalize apically in the less
differentiated daughter cell during asymmetric cell division.
Par3 exerts its effect by direct interaction with Numb and
Numb-like (Numbl) and thereby modulating its antagonistic
effect on Notch signaling (Bultje et al., 2009). Meanwhile,
Msi1 augments Notch signaling through the translational
repression of Numb, thereby contributing to NSC self-renewal
(Okano et al., 2005).
In fact, gliogenesis is a predominant process over
neurogenesis in the adult brain. This neurogenic-gliogenic
switch, which is a characteristic feature of the developed
nervous system, requires the expression of the mitogen
activated protein (MAP) kinase kinases Mek1 and Mek2,
Notch pathway proteins and the Signal transducer and
activator of transcription 3 (STAT3) signaling members.
Meanwhile, astrocytes emerge from the glial-restricted precursor
expressing A2B5, whereas oligodendrocytes develop from
oligodendrocyte progenitor cells expressing such signatures
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FIGURE 3 | Cellular and molecular regulators of glioma CSC quiescence in the niche. CSCs can regulate their own state by autocrine mechanism by producing
differentiation antagonists (Germlin1) or poise themselves to active growth by synthesizing PEDF and EGF, or by expressing constitutively active form of EGFR
(EGFRviii). CSCs can attract immune cells by releasing proinflammatory cytokines (MCP1 for monocytes, IL6 and IL8) and induce their immunosuppressive
phenotype (M1 macrophages transform into tumor-associated macrophages (TAMs), effector T cells are induced to T regulatory cells (T regs)) by producing TGFβ. In
turn, induced tumor-associated immune cells favor the CSC state by producing TGFβ. Mesenchymal cells CXCL12 can activate PI3K/Akt, IP3 and mitogen activated
protein kinase (MAPK) pathways via CXCR4 and PLC/MAPK pathway via CXCR7. IL-8 supports glioma CSCs growth and migration towards endothelial cells. CSCs
also regulate their nutrition supply by inducing neo-vascularization via vascular endothelial growth factor (VEGF) production. Stromal cells producing Wnt5a can
induce CSC quiescence via Ryk receptor. Differentiated tumor cells can regulate CSCs state via cell-cell contact through Notch signaling.
as Olig2, NG2 proteoglycan and platelet-derived GFR-alpha
(PDGFRA). Nevertheless, in the adult brain there are two
remaining sites of neurogenesis: the SVZ and the SGZ. In
these regions, a subpopulation of outer radial glial cells,
characterized by glial fibrillary acidic protein (GFAP) and
Nestin expression, act as NSCs (Pollen et al., 2015). These
NSCs from adult brain, are also known as type B cells, can
produce transit-amplifying progenitors, also termed type C cells,
which will divide a finite number of times until they become
differentiated (Doetsch et al., 1997), and oligodendrocyte
precursor cells (OPCs), which can generate neuroblasts (type A
cells; Doetsch et al., 1999), and oligodendrocytes (Menn et al.,
2006), respectively.
Glioma CSC Stemness Preservation and
Plasticity
Glioma CSCs are thought to arise from NSCs in SVZ. A recent
report by Lee et al added a robust confirmation to this theory,
as they were able to demonstrate that astrocyte-like NSCs from
the tumor free SVZ frequently share similar genetic alterations
with matched tumor from the same patient, especially in the
TERT promoter region. Although it is possible that early stage
glioma cells migrate to the tumor-free SVZ and initiate a pool
of NSCs with low level of GBM mutations, it is more likely
that astrocyte-like NSCs from the SVZ are precursor cells for
glioma CSCs (Lee et al., 2018). As glioma CSCs and NSCs
share a lot of common features, glioma CSCs were suggested
to have reminiscent differentiation hierarchy characterized by
embryonic stem cells at the beginning, which subsequently
generate transit amplifying cells, lineage-committed progenitors
and mature cells. In order to create a hierarchical model
of glioblastoma CSC differentiation, Bradshaw et al. (2016)
systematized all the known putative phenotypic markers of
GBM CSCs. They divided the GBM CSCs into two classes;
those expressing markers associated with an embryonic stem
cell phenotype and expressing Nanog, Sall4, Oct-4, Klf4, Sox2,
and those that acquired a neuronal stem cell phenotype with
CD133 and CD44 expression. There is a possibility to expand
this classification by assuming that glioma CSCs can acquire
differentiation markers common for normal glia and neurons. In
this way, stages of CSC differentiation can be distinguished by
rising progenitor cell markers (PSA-NCAM and Doublecortin;
van Strien et al., 2011) and terminal differentiation markers of
oligodendrocytes (ASCL1, OLIG2, DLL3), astrocytes (GFAP),
neurons (β-tubulin III, SYT1 and SLC12A5), and markers of
inflamed astroglial cells (SERPINE1, TGFB1, RELB; Sullivan
et al., 2014). The probable glioma CSCs hierarchy is represented
in Figure 2B. However, cell surface phenotypic markers do not
always properly reflect the current cell state, and this model is not
fully complete as it is missing themarkers of finite differentiation.
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Additionally, the glioma CSC secretome was found to change
during distinct differentiation stages and it was demonstrated
that quiescent glioma CSCs do not secrete any cytokines,
but maturation stimulation causes them to produce different
cytokines at different times, beginning with the production of
EGF on the 2nd day of differentiation, MCP1 on the 3rd, VEGF
on the 4th, IL8 on the 9th and PDGF on the 18th day of
differentiation (Kwak et al., 2013).
The population of glioma CSCs shares a number of intrinsic
similarities with NSCs, which includes expression of stem cell
markers such as CD133, self-renewal ability and the generation
of multi-lineage progeny. In terms of common molecular
signatures, both NSCs and glioma CSCs exhibit Y-box binding
protein 1 (YB-1), Sox-2, Nestin and Msi1 expression which
are lost upon differentiation (Fotovati et al., 2011; Chao et al.,
2017). Additionally, glioma CSCs are able to give rise to different
neuronal and glial-like cells (Natsume et al., 2013; Bulstrode
et al., 2017), which highlights a possible mechanism of glioma
CSCs retaining stem cell properties by undergoing asymmetric
division. Indeed, the capability to divide asymmetrically with
uneven distribution of CSC markers (such as CD133) was
reported for glioma cells with stem cell properties (Lathia
et al., 2011b), suggesting that asymmetric division may play
an important role in tumor maintenance. Moreover, glioma
stem cell division showed asymmetry in the distribution pattern
of other key stem cell markers, such as Numb, EGFR and
Nestin (Cusulin et al., 2015). Numb is a main controller of
asymmetric cell division and has been found to be asymmetrically
segregated between daughter cells of dividing glioblastoma
CSCs, where it colocalized with prominin 1 (CD133; Jiang
et al., 2012). Additionally, the asymmetric distribution of the
main astrocytic intermediate filament, GFAP, was shown for
a small fraction of glioma CSCs (Guichet et al., 2016). Thus,
asymmetric division can be a mechanism by which glioma
CSCs preserve stem properties whilst also generating the
whole repertoire of heterogenic tumor cells within the bulk
tumor.
However, other studies have accumulated evidence
supporting an alternative theory, postulating that CSCs
arise from the inability of transformed NSCs to undergo
asymmetric division, leading to continuous symmetric mitosis.
As an example, the loss of p53 in cancer was shown to
favor symmetrical cell division, while the restoration of
p53 was correlated with rescued asymmetric cell division
(Cicalese et al., 2009). Therefore, it is also possible that
an aberrant increase in symmetrical cell divisions in NSCs
contributes to normal cells acquiring a CSC phenotype.
Another possibility is that driver mutations occur in NSCs but
the actual malignant transformation afflicts their derivative
oligodendrocyte progenitor cells or astrocyte precursors. The
mechanisms by which p53 mutations affect asymmetry in
NSC division are not fully understood, but it would be of
interest to investigate if there is a lineage or maturity-specific
impact of p53 mutations on the cell differentiation in the
brain. Despite p53 mutation not being solely sufficient for
astrocytoma formation, it causes an increase in proliferation
rate (Gil-Perotin et al., 2006). Additionally, dominant negative
p53 can force quiescent stem cells to proliferate and but do
not lead to cell differentiation (Ehtesham and Khan, 2015),
and in combination with IDH R132H substitution leads to
cancer transformation reminiscent of low-grade gliomas (IDH1-
mutant TP53 lost astrocytomas; Modrek et al., 2017). Upon
introduction of TP53 and NF1 mutations into adult OPCs,
they become reactivated and reach the proliferative rate of
perinatal OPCs. Interestingly, mutant OPCs firstly turned
to a dormant state, until a few cells escaped quiescence and
only then malignant transformation ensued (Galvao et al.,
2014). This could reflect the physiological process occurring
during glioma establishment, when normal slow-cycling stem
cells transform into a malignant state, but remains dormant
until a specific signal from the surrounding milieu awakes
them.
In favor of the symmetrical hypothesis of arising glioma
CSCs, it was shown that decreased asymmetry in distribution
of neural/glial antigen 2 (NG2), which is a proteoglycan
required for normal OPC division, correlates with premalignant,
abnormally increased self-renewal and with tumor-initiating
potential in the OPC progeny. NG2 is needed for asymmetric
segregation of EGFR+ cells to the NG2+ progeny, which
is conferred with increased EGF-dependent proliferation
and self-renewal, whereas the NG2− progeny differentiate
(Sugiarto et al., 2011). Wnt signaling was also proved to
contribute to asymmetric brain cell mitosis. Wnt, through
the actions of β-catenin, directed asymmetric inheritance
of centrosomes and promoted expression of pluripotency
genes in β-catenin+ daughter cells (Habib et al., 2013).
However, GBM CSCs treated with Wnt activators exhibited
decreased proliferation ability and were committed to neuronal
differentiation (Rampazzo et al., 2013). Additionally, single-cell
RNA sequencing of IDH1-mt gliomas revealed the presence
of a normal differentiation program in glioma CSCs across
two lineages: astrocytes and oligodendrocytes. It also identified
a small population of highly cycling cells with expressed
stem cell genes, suggesting that low grade gliomas contain
conventional hierarchy with a small population of tumor
amplifying cells dividing in normal symmetric fashion (Tirosh
et al., 2016).
Thus, glioma CSCs have an additional way of preserving the
quiescent cell population, i.e., by asymmetric division allowing
preservation of stem cell properties and genetic stability over
time. This asymmetry in glioma CSCs is ensured by different
distribution of the GFR (EGFR) molecules, transcription
factors (e.g., Oct4, Sox2, etc.), membrane glycoproteins and
proteoglycans (CD133, NG2) regulating stem cell properties
and suppressing differentiation. Markedly, several mutations
(p53, NF1) can favor symmetric cell division, which allows to
put forward an alternative explanation for the gliomagenesis,
i.e., via disrupting the normal asymmetric division of NSCs.
The pathways influencing symmetric and asymmetric division of
stem cells are summarized in Figure 2C. All in all, the evident
contribution of both symmetric and asymmetric cell division
plays a role in the aforementioned processes, and highlights
the need for a better understanding of the fine molecular
mechanisms behind either preservation or the initiation of
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the CSC quiescence. It also warrants the fine tuning of
in vitro cell based models available to both basic researchers
and clinicians to explore this phenomenon (Mikhailova et al.,
2018).
GLIOMA CSC NICHE
Another mechanism which can support glioma CSC quiescence
is associated with niche factors. ‘‘Niche’’ refers to the
microenvironment within the specific anatomic location
where stem cells interact with other cells or ECM, providing
them with stimuli that restrains them from maturation and
sustains replication ability. Niche residence can also protect stem
cells from aqcuiring mutational errors (Schofield, 1978).
Glioma Associated Cells
There is no consesus about niche cells or ECM components
contributing to microenvironment of stem cells. Recently, it
was shown that stem cell progeny provide feedback signals
for quiescence or symmetric/assymetric division to stem cell
therefore acting as niche cells (Redondo et al., 2017). This
feedback includes stimuli to maintain quiescence and preclude
excessive or unneeded activation, thus preserving a functional
pool of stem cells. Additionally, matured astrocytes were shown
to facilitate NSCs proliferation via Wnt7a by activating β-
catenin–cyclin D1 pathway or can promote differentiation via
β-catenin–neurogenin 2 pathway (Qu et al., 2013). Moreover,
it was shown that removal of terminally differentiated cells
from the stem cell niche massively activates quiescent stem
cells (Hsu et al., 2011). Niche cells surround the stem cell
and collect signals provided by the tissue or more distant
sites while maintaining the local microenvironment. Long
lasting signals or signals with sufficient threshold will be
firstly received by the cells in the local milieu which will
in turn regulate stem cell behavior (So and Cheung, 2018).
In support of this theory, recently, it has been revealed
that molecules produced at the site of injuries do not
reach stem cells directly, but are translated into stimuli that
reprogram niche cells and ECM surrounding stem cells, thus
priming quiescent stem cells for activation (Rodgers et al.,
2014).
However, tumors are composed of cells that do not
respond to external proliferative or static stimulation and are
able to evade growth suppression and death signals from
the local microenvironment. Another characteristic feature is
that cancer cells modulate neighboring cells by producing
cytokines or expressing immunosuppressive ligands (Hanahan
and Weinberg, 2011). The glioma CSC microenvironment
mainly consists of differentiated tumor cells, endothelial cells,
pericytes, fibroblasts, normal glia, neurons and immune cells
(see Figure 3). The cytoarchitecture of glioma consists of
peripheral normoxic tumor cells and hypoxic tumor cells
residing in the center as well as necrotic cells in the
inner cores (Lathia et al., 2011a). This niche cells maintain
glioma CSCs in a dormant state preserving their potential
to proliferate and differentiate, at the same time protecting
them from chemo- and radiotherapy (Sanai et al., 2005).
Glioma CSCs are thought to localize in close proximity to
perivascular niches (Flavahan et al., 2013). Glioma CSCs may
produce VEGF, promoting vessel growth, while endothelial
cells cocultured with glioma CSCs, facilitated the CSC-like
phenotype of glioma cells by increasing the expression of
Sox2, Olig2 and Bmi1 (Fidoamore et al., 2016). Moreover,
endothelial cells may maintain glioma CSC properties by
activating the Hedgehog signaling pathway (Yan G. N. et al.,
2014). Interestingly, the glioma CSCs may contribute directly
to tumor neovascularization, because they can transdifferentiate
into endothelial cells (Ricci-Vitiani et al., 2010). Furthermore,
glioma CSCs are capable of generating pericytes, indicating an
active role for CSCs in the building of an appropriate niche
supplied with additional vasculature and nutrients (Cheng et al.,
2013).
Additionally, CSCs and endothelial cells combined within
the tumor microenvironment can transform normal fibroblasts
into cancer-associated fibroblasts (CAFs) possessing increased
proliferation and secreting unique cytokines, such as CXCL12,
VEGF, PDGF and HGF (Junttila and de Sauvage, 2013).
CAFs cocultured with glioma CSCs were shown to serve as
feeder cells to supply stemness factors, while their removal
led to decreased expression of stem cell markers such as
Oct4 and Nanog followed by partial CSC differentiation
(Chen et al., 2014). Reciprocally, inhibition of Notch signaling
leads to detachment of glioma CSCs from their vascular
niche, resulting in increased efficacy of radiotherapy (Hovinga
et al., 2010). However, PEDF may also regulate Notch to
contribute to stemness in the vascular niche (Andreu-Agullo
et al., 2009). Glioma CSCs can produce PEDF and engage
in their own autocrine regulation of self-stemness/-renewal,
which occurs by activation of EGFRvIII/STAT3/PEDF or
Notch/Sox2 signaling.
Mesenchymal stem cells were also reported to contribute
to multiple mechanisms favoring cancer cell proliferation,
including fostering vasculogenesis and inducing local
immunosuppressiveness (Nishimura et al., 2012). These
cells can secrete a variety of cytokines promoting cancer
stemness through NF-κB pathway, such as CXCL12, IL6
and IL8 (Cabarcas et al., 2011). CXCL12 controls normal
stem cell homing in the brain and maintains stem cells
in their niche (Maksym et al., 2009). However, in glioma
CXCL12 can activate PI3K/Akt, IP3 and MAPK pathways via
CXCR4 (Boldajipour et al., 2008) and PLC/MAPK pathway
via CXCR7 resulting in increased cell survival in the quiescent
state. Interestingly, CXCR4/CXCL12 signaling is remarkably
active in the areas surrounding necrotic foci, which contain
increased number of quiescent CSCs (Zagzag et al., 2008).
IL8 effects are exerted via binding to CXCR1 and CXCR2,
which mediates the invasion of glioma cells (Zhu et al.,
2012). Recent findings describe IL-8 as a critical mediator
in supporting glioma CSC growth and migration towards
endothelial cells, which is one of the possible mechanisms
forcing their perivascular colocalization within the tumor niche
(Infanger et al., 2013).
Additionally, mesenchymal stem cells attracted to
the glioma CSC niche can stimulate tumor progression
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by producing the BMP antagonist, Gremlin 1, which
antagonizes differentiation signals through the inhibition
of p21WAF1/CIP1, which is a key CSC signaling node.
BMP family members stimulate NSCs to differentiate to
astrocytes, and therefore, they were proposed as candidates
for application in anti-CSC therapies, as per they could assist
CSCs differentiation (Carén et al., 2016), but, paradoxically,
gliomas express high levels of BMPs. However, it was further
demonstrated that glioma CSCs highly express Gremlin1 as
their protection from endogenous BMP (Yan K. et al.,
2014).
Glioma CSCs are capable of recruiting numerous cell types
by secreting chemokines. Cytokines attract and induce tumor-
associated macrophages (TAMs), tumor-associated neutrophils
and other suppressor cells. Attractedmacrophages secrete TGF-β
and recruit T regulatory cells (Tregs) that ensure maintenance of
immunosuppression conditions (Chanmee et al., 2014). Induced
immunosuppressive cells protect the tumor by producing IL6,
TGF-β and TNFα, upregulating the NF-κB molecular pathway
which in turn activates Snail, Slug and Twist to stimulate
self-renewal (Kitamura et al., 2015).
In normal stem cell niches, tight attachment of stem cells
to the niche through cell-cell contacts is crucial for preventing
their differentiation and for localizing factors that maintain
self-renewal physically adjacent to niche (Borovski et al., 2011).
CSCs also anchor to their niche cells to preserve stemness,
as direct cell contact is particularly necessary for Hedgehog
and Notch pathways. However, Notch signaling was shown to
inhibit brain tumor initiation and growth, although, it is possible
that transformed glioma cells were turned to a quiescent state
(Giachino et al., 2015). Meanwhile, normal glial cells may also be
utilized for cell-to-cell contacts to tether glioma cells (Riquelme
et al., 2008).
Glioma Associated Extracellular Matrix
Apart from neo-vascularization and the effects of immune
and stromal cells within the tumor microenvironment, an
important role is played by the ECM, which confers the
structural scaffold. It contains fibrous proteins such as elastin,
collagens, fibronectin, laminins, as well as cellular proteases,
such as cathepsins, matrix metalloproteinases and kallikreins,
as well as globular proteins including integrins (Melzer et al.,
2016). Laminin from tumor cells can alter glioma CSC
phenotype derived from the perivascular niche (Lathia et al.,
2012). Moreover, laminin-111 was shown to induce quiescence
of breast epithelial cells in a three-dimensional cell culture
system by depleting nuclear-associated actin (Spencer et al.,
2011).
Still it is evident that the tumor milieu provides supporting
growth signals, protection from active immune cells and
contributes to therapy resistance. However, the nature of CSC
regulation by its tumor niche remains unresolved. An intriguing
question is whether the CSC fate is regulated by intrinsic
(autocrine or autonomous) stimuli or through interactions with
the local environment. Another open question is if CSCs within
their local niche are confined to a closed domain that is not
receiving systemic stimuli.
CONCLUDING REMARKS AND FUTURE
DIRECTIONS
Taken together, in healthy conditions a quiescent state
protects normal stem cells from senescence and exhaustion
thus preserving the multipotent ability to reconstitute brain
components. Recent findings support the hypothesis that all
remote stimuli affect stem cells not by direct stimulation but
rather by changing the niche state which in turn regulates
resident stem cells, thus protecting them from unnecessary
activation. In a disease state, glioma CSCs can also preserve
stem cell properties by actively changing the oxygen supply,
nutrient availability and regulating the state of different
neighboring cells. Glioma CSCs have several major molecular
mechanisms implicated in maintaining their active quiescent
state. Those mechanisms include the aberrant expression of
the genes facilitating key regulatory processes. Such processes
include altered cellular growth and survival, which commonly
happen due the acquisition of the mutations leading to either
constitutive EGFR activation (EGFRvIII), or GOF IDH1/2 and
p53 mutations, globally affecting gene expression and other
chromatin-dependent processes. Additionally, glioma CSCs
can preserve their stem cell properties by their ability to
asymmetrically divide which allows simultaneous retention of
replication ability and genome stability while propagating the
tumor mass. This point also favors the theory that high-grade
gliomas most probably originate from NSCs in the brain SVZ. In
addition, glioma CSCs actively change their microenvironment,
creating a comfortable cancer niche by attracting endothelial
cells for vessel construction and inducing immune cells to the
immunosuppressive state. Thus, glioma CSCs possess a wide
range of survival mechanisms to evade targeted therapy as
blockage of one specific pathway will be compensated by a range
of other overlaying molecular cascades. The promising option
to overcome this problem is differentiation therapy which may
force glioma CSCs to purposefully re-enter the cell cycle in order
to be eliminated by chemotherapy when they are no longer
protected by a dormant state. Unfortunately this option has
certain disadvantages, as induction of tumor cell proliferation
is not an ideal treatment, however, in the case of high-grade
cancers, treatment almost always implies the hard choice between
possible complications and a possible benefit from treatment.
Thus, future perspectives include therapeutic manipulations of
the stem cell niche to induce differentiation of glioma CSCs as a
novel approach of anticancer therapy.
Another possibility is to carefully assess disease development
in each patient and reveal the dominant cancer maintaining
mechanism by considering the particular glioma molecular
profile (genetic alterations/aberrant gene expression), thus
bringing glioma treatment to the era of precision medicine. In
this case, some patients can be treated with immunotherapy,
interfering with several important pathways by treatments
such as TGFb inhibitors and agents blocking secretion of
anti-inflammatory factors. It is also possible to push CSC
differentiation by blocking BMP and EGFR mediated signals,
to prevent tumor vascularization by inhibiting VEGF, to
increase tumor sensitivity by interfering with niche adhesion
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molecules (N-Cadherin and VCAM1). In addition, finding the
markers for quiescent CSCs may contribute to their specific
eradication by targeted therapy. Further understanding the CSC
developmental hierarchy and mechanism of choice between
quiescent or proliferative state will allow new approaches to
glioma therapy.
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